google-site-verification: googlec7193c3de77668c9.html

Donanemab: NHS will not fund new drug to slow Alzheimer’s

People do not get better on donanemab. It is not a cure for Alzheimer’s disease, but it slows the progression of the disease.

It works by clearing a sticky protein from the brain – called amyloid – which is one of the hallmarks of Alzheimer’s.

The drug was earlier given a licence to be used in the UK, which means it can be prescribed privately.

However, NICE has ruled it would not be a good use of taxpayers’ money and was five-to-six times more expensive than the NHS normally considers acceptable.

It said the drug slowed cognitive decline by four to seven months in trials.

“This is just not enough benefit to justify the additional cost to the NHS,” said Helen Knight, director of medicines evaluation at NICE.

“I know this will be disappointing news, but this is an emerging field of medicine and there are other treatments being developed.”

It is estimated that around 70,000 adults in England would have been eligible for treatment with donanemab.


Source link

Views: 1

See also  Metabolic dysfunction is main driver of chronic kidney disease risk

Check Also

AI support tool improves clinician decisions in real-world primary care trial

[ Credit: Unsplash/CC0 Public Domain A large real-world clinical trial has found that a generative …

How heat waves are dangerous to human health

[ A punishing heat wave overwhelming hospitals in Europe is just the latest reminder of …

Blood vessel cells keep fixed signaling roles for weeks, reshaping view of capillary communication

[ Credit: The Greco Lab. Proceedings of the National Academy of Sciences (2026). DOI: 10.1073/pnas.2519708123 …

Leave a Reply

Available for Amazon Prime
You have been rate limited for making too many requests in a short time frame.